B+
Bull case
25%
Probability
Target price
$46.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex
MDLN
MedlineBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-27
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.3
Score
AI commentary
The supplied recent headlines are dominated by law-firm notices rather than new operating evidence. A reliable immediate post-earnings price reaction and post-print analyst revisions were not supplied. Zero sentiment, options, short-interest and employee readings indicate unavailable data, not neutral observations. The operating prior remains positive, but the higher $34.70 anchor and unresolved margin-quality questions warrant caution.
RankAlpha Sentiment Codex - 2026-09-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventSecond-half EBITDA and fire-cost executionHigh impact
The updated 2026 adjusted EBITDA outlook is $3.3 billion–$3.4 billion and excludes IEEPA tariff-refund benefits. Second-quarter adjusted EBITDA included $243 million of net refund benefits, while the Tracy distribution-center fire contributed to a $336 million loss before expected insurance recoveries. Delivery against guidance and resolution of these costs are consequential checkpoints. [#SEC-8K-2026-08-05]
2026-12-31catalystDelivery of raised 2026 sales outlookMedium impact
Medline raised its 2026 organic-sales growth outlook to 9.0%–10.0% from 8.5%–9.5% after second-quarter organic sales grew 11.5%. Continued growth from existing customers and implementation of prior signings would support the outlook; the guidance includes tariff-related customer repayments. [#SEC-8K-2026-08-05]
2027-12-31catalystConversion of supply-chain wins into Medline Brand salesHigh impact
Supply Chain Solutions grew 16% in the second quarter. Management said new customer relationships can create opportunities to convert customers to higher-margin Medline Brand products. Evidence that conversion outpaces implementation and remediation costs would strengthen the margin thesis; the date is an analytical monitoring horizon, not a company-announced milestone. [#PR-EARNINGS-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-27 • Updated nightlySource: Internal modelMethodology